Biointron

Executive Summary

Biointron is a private, US-based contract research organization (CRO) founded in 2012 and headquartered in Cambridge, Massachusetts. The company specializes in high-throughput, automated antibody discovery, production, and optimization services for biotechnology and pharmaceutical clients. ISO 9001:2015 certified, Biointron emphasizes rapid turnaround, offering delivery of recombinant antibodies from gene sequence in as little as two weeks. With a focus on efficiency and scalability, the company serves the growing demand for antibody therapeutics and research reagents. While Biointron operates in a competitive CRO landscape, its specialization in antibody services and commitment to speed position it as a niche player. The company is currently in an early stage (Phase 1) and has not disclosed funding or valuation. Its success hinges on continued client acquisition, technological advancements, and potential strategic partnerships to expand its market reach.

Upcoming Catalysts (preview)

• Q4 2026Launch of next-generation automated antibody discovery platform70% success
• Q3 2026Strategic partnership with a top-20 pharmaceutical company60% success
• Q1 2027Expansion of service portfolio to include bispecific antibody development65% success